Predictors of Health-Related Quality of Life and Adherence in Crohn’s Disease and Ulcerative Colitis: Implications for Clinical Management

Digestive Diseases and Sciences

Volumn 60, Issue 5, 2015, Pages 1366-1374

  Tabibian, Anilga ^a,b   Tabibian, James H ^a   Beckman, Linda J ^b   Raffals, Laura L ^a   Papadakis, Konstantinos A ^a   Kane, Sunanda V ^a  

^a MAYO CLINIC   (United States)

^b ALLIANT INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Inflammatory bowel disease; Integrated care; Patient education; Perceived stress

Indexed keywords

ADOLESCENT; ADULT; AGED; ATTITUDE TO HEALTH; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; MENTAL STRESS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; RECURRENT DISEASE; RISK FACTOR; SEX DIFFERENCE; STATISTICAL MODEL; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; QUALITY OF LIFE; QUESTIONNAIRES; RECURRENCE; RISK FACTORS; SEX FACTORS; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84937965331     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3471-1     Document Type: Article

References (45)

1. De Schepper HU, De Man JG, Moreels TG, Pelckmans PA, De Winter BY. Review article: gastrointestinal sensory and motor disturbances in inflammatory bowel disease—clinical relevance and pathophysiological mechanisms. Aliment Pharmacol Ther. 2008;27:621–637.
2. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–1657.
3. Devlen J, Beusterien K, Yen L, Ahmed A, Cheifetz AS, Moss AC. The burden of inflammatory bowel disease: a patient-reported qualitative analysis and development of a conceptual model. Inflamm Bowel Dis. 2014;20:545–552.
4. Dudley-Brown S. Prevention of psychological distress in persons with inflammatory bowel disease. Issues Ment Health Nurs. 2002;23:403–422.
5. Sainsbury A, Heatley RV. Review article: psychosocial factors in the quality of life of patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;21:499–508.
6. Van der Have M, van der Aalst KS, Kaptein AA, et al. Determinants of health-related quality of life in Crohn’s disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8:93–106.
7. Casellas F, López-Vivancos J, Casado A, et al. Factors affecting health related quality of life of patients with inflammatory bowel disease. Qual Life Res. 2002;11:775–781.
8. Robinson A. Review article: improving adherence to medication in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:9–14.
9. Devlen J, Beusterien K, Yen L, Ahmed A, Cheifetz AS, Moss AC. Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis. J Manag Care Pharm. 2014;20:309–314.
10. Van der Eijk I, Stockbrügger R, Russel M. Influence of quality of care on quality of life in inflammatory bowel disease (IBD): literature review and studies planned. Eur J Intern Med. 2000;11:228–234.
11. Irvine EJ. Quality of life issues in patients with inflammatory bowel disease. Am J Gastroenterol. 1997;92:18S–24S.
12. Drossman DA, Patrick DL, Mitchell CM, et al. Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig Dis Sci. 1989;34:1379–1386.
13. Moradkhani A, Beckman LJ, Tabibian JH. Health-related quality of life in inflammatory bowel disease: psychosocial, clinical, socioeconomic, and demographic predictors. J Crohns Colitis. 2013;7:467–473.
14. Jaghult S, Saboonchi F, Johansson U, Wredling R, Kapraali M. Identifying predictors of low health related quality of life among patients with inflammatory bowel disease: comparison between Crohn’s disease and ulcerative colitis with disease duration. J Clin Nurs. 2011;20:1578–1587.
15. Rubin G, Hungin AP, Chinn D, et al. Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. Aliment Pharmacol Ther. 2002;16:1889–1893.
16. Bernal I, Domènech E, Garcia-Planella E, et al. Medication-taking behaviour in a cohort of patients with inflammatory bowel disease. Dig Dis Sci. 2006;51:2165–2169.
17. San-Román AL, Bermejo F, Carrera E, Pérez-Abad M, Boixeda D. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig. 2005;97:249–257.
18. Selinger CP, Eaden J, Jones DB, et al. Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2199–2206.
19. Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis—strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther. 2008;27:1157–1166.
20. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:191–198.
21. Thia K, Faubion WA, Loftus EV, Persson T, Persson A, Sandborn WJ. Short CDAI: development and validation of a shortened and simplified Crohn’s Disease Activity Index. Inflamm Bowel Dis. 2011;17:105–111.
22. Walmsley RS, Ayers RCS, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43:29–32.
23. Higgins PDR, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission clinical improvement in ulcerative colitis. Gut. 2005;54:782–788.
24. Guyatt G, Mitchell A, Irvine JE, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96:804–810.
25. Kravitz RL, Hays RD, Sherbourne CD, et al. Recall of recommendations and adherence to advice among patients with chronic medical conditions. Arch Intern Med. 1993;153:1869–1878.
26. Cohen S, Williamson G. Perceived stress in a probability sample of the United States. In: Spacapan S, Oskamp S, eds. The Social Psychology of Health. Newbury Park, CA: Sage; 1988.
27. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24:386–396.
28. Eaden JA, Abrams K, Mayberry JF. The Crohn’s and colitis knowledge score: a test for measuring patient knowledge in inflammatory bowel disease. Am J Gastroenterol. 1999;94:3560–3566.
29. Duffy LC, Zielezny MA, Marshall JR, et al. Lag time between stress events and risk of recurrent episodes of inflammatory bowel disease. Epidemiology. 1991;2:141–145.
30. Levenstein S, Prantera C, Varvo V, et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol. 2000;95:1213–1220.
31. Bitton A, Sewitch MJ, Peppercorn MA, et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroenterol. 2003;98:2203–2208.
32. Bitton A, Dobkin P, Edwardes MD, et al. Predicting relapse in Crohn’s disease: a biopsychosocial model. Gut. 2008;57:1386–1392.
33. Graff LA, Walker JR, Clara I, et al. Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J Gastroenterol. 2009;104:2959–2969.
34. Rogala L, Miller N, Graff LA, et al. Population-based controlled study of social support, self-perceived stress, activity and work issues, and access to health care in inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:526–535.
35. Drossman DA. The role of psychosocial factors in gastrointestinal illness. Scand J Gastroenterol. 1996;221:1–4.
36. Duffy LC, Zielezny MA, Marshall JR, et al. Relevance of major stress events as an indicator of disease activity prevalence in 489 inflammatory bowel disease. Behav Med. 1991;17:101–110.
37. Casellas F, López-Vivancos J, Badiac X, et al. Impact of surgery for Crohn’s disease on health-related quality of life. Am J Gastroenterol. 2000;95:177–182.
38. Hjortswang H, Järnerot G, Curman B, et al. The influence of demographic and disease-related factors on health-related quality of life in patients with ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15:1011–1020.
39. Thirlby RC, Land JC, Fenster LF, et al. Effect of surgery on health-related quality of life in patients with inflammatory bowel disease: a prospective study. Arch Surg. 1998;133:826–832.
40. Cerveny P, Bortlík M, Kubena A, Vlcek J, Lakatos PL, Lukás M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis. 2007;13:1244–1249.
41. Kane SV. Strategies to improve adherence and outcomes in patients with ulcerative colitis. Drugs. 2008;68:2601–2609.
42. Sajadinejad MS, Asgari K, Molavi H, Kalantari M, Adibi P. Psychological issues in inflammatory bowel disease: an overview. Gastroenterol Res Pract. 2012;2012:1–11. doi:10.1155/2012/106502.
43. Rowlinson A. Inflammatory bowel disease 3: importance of partnership in care. Br J Nurs. 1999;8:1013–1018.
44. Goldring AB, Taylor SE, Kemeny ME, Anton PA. Impact of health beliefs, quality of life, and the physician–patient relationship on the treatment intentions of inflammatory bowel disease patients. Health Psychol. 2002;21:219–228.
45. Nguyen GC, LaVeist TA, Harris ML, Datta LW, Bayless TM, Brant SR. Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1233–1239.